Key Highlights

  • Operating loss grew to USD 2.96 million from USD 2.45 million.
  • Total costs and expenses climbed 20.5% to USD 2.98 million.
  • Research and development costs were USD 846 thousand, versus USD 607 thousand.
  • Nine-month net loss was USD 9.95 million, versus USD 9.78 million.

AIM ImmunoTech (NYSE American:AIM) lost USD 2.96 million at the operating level in the third quarter of 2026, against USD 2.45 million in the third quarter of 2025. The numbers come from its filing for the quarter ended September 30, 2026.

Total costs and expenses rose 20.5%, to USD 2.98 million from USD 2.47 million. Interest and other income was USD 74 thousand, against USD 3.05 million.

What Drove the Cost Increase

Research and development costs jumped 39.4%, to USD 846 thousand from USD 607 thousand. General and administrative costs rose 18.2%, to USD 2.13 million from USD 1.80 million, which the filing puts down to higher salaries and director fees.

Across the nine months ended September 30, 2026, Research and Development cost USD 1.92 million, against USD 2.86 million, while general and administrative costs came to USD 6.83 million, against USD 5.83 million. Total costs and expenses were USD 8.77 million, against USD 8.78 million, and the operating loss was USD 8.70 million, against USD 8.71 million.

The nine-month net loss was USD 9.95 million, against USD 9.78 million. In the cash flow statement, Depreciation and amortization was USD 852 thousand, against USD 559 thousand, and investments produced a loss of USD 3 thousand, against a gain of USD 17 thousand.

Ampligen and the Pancreatic Cancer Focus

Ampligen has neither FDA approval nor a presence on the US market, the filing says, though it carries approval for commercial sale in Argentina, where it treats severe chronic fatigue syndrome. On the strength of clinical results on safety and efficacy from its pancreatic cancer early access program and an ongoing Phase 2 trial, the company has decided to concentrate on developing Ampligen for late-stage pancreatic cancer. It believes this path could prove the most valuable.

Liquidity and the Going Concern Language

The filing explains that when substantial doubt exists about the company's ability to continue as a going concern, management weighs whether its plans sufficiently offset that doubt. The conditions it describes, the filing says, raise substantial doubt for a period of at least one year from the date the financial statements were issued.

Cash and cash equivalents were USD 6.89 million at September 30, 2026, against USD 2.99 million at the prior Balance Sheet date, and marketable securities were USD 61 thousand, against USD 62 thousand. Cash and cash equivalents rose by USD 3.90 million over the nine months, against a USD 646 thousand rise a year before.

The Quarter in Brief

AIM ImmunoTech reported an operating loss of USD 2.96 million and total costs and expenses of USD 2.98 million for the quarter. The nine-month net loss was USD 9.95 million.